Cargando…

Serrated Pathway Adenocarcinomas: Molecular and Immunohistochemical Insights into Their Recognition

INTRODUCTION: Colorectal adenocarcinomas (CRC) developed through serrated pathway seem to present particular behavior compared with the non-serrated ones, but recognition of them is difficult to do. The aim of our paper was to establish some criteria to facilitate their identification. MATERIALS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurzu, Simona, Szentirmay, Zoltan, Toth, Erika, Bara, Tivadar, Jung, Ioan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587644/
https://www.ncbi.nlm.nih.gov/pubmed/23469219
http://dx.doi.org/10.1371/journal.pone.0057699
_version_ 1782261429546516480
author Gurzu, Simona
Szentirmay, Zoltan
Toth, Erika
Bara, Tivadar
Bara, Tivadar
Jung, Ioan
author_facet Gurzu, Simona
Szentirmay, Zoltan
Toth, Erika
Bara, Tivadar
Bara, Tivadar
Jung, Ioan
author_sort Gurzu, Simona
collection PubMed
description INTRODUCTION: Colorectal adenocarcinomas (CRC) developed through serrated pathway seem to present particular behavior compared with the non-serrated ones, but recognition of them is difficult to do. The aim of our paper was to establish some criteria to facilitate their identification. MATERIALS AND METHODS: In 170 consecutive CRCs, we performed immunohistochemical staining with Cytokeratin 7 (CK7) and Cytokeratin 20 (CK20) and also with p53 and MLH-1. At the same time, we analyzed BRAF and K-ras mutations and the microsatellite status of CRC. RESULTS: 26.47% of cases expressed CK7, and 16.47% were CK20-negative. Diffuse positivity for CK7 was associated in the proximal colon with CK20 negativity or weak positivity, BRAF mutations, lack of K-ras mutations, and p53 and MLH-1 negativity. All these cases were microsatellite-unstable and were diagnosed in stage II. Those cases from the distal colon and rectum that expressed CK7 were K-ras-mutated and had low p53 index and MLH-1 positivity, independent of the CK20 expression. CONCLUSIONS: CK7, associated with MLH-1 and p53 expression, and also with the microsatellite status, BRAF and K-ras pattern, might be used to identify the CRC potentially going through serrated pathway. The serrated pathway adenocarcinomas of the proximal colon that do not display the morphological features of this pattern are more frequent CK7+/p53−/MLH-1−/BRAF-mutated/K-ras-wt/MSI cases, but those located in the distal colorectal segments seem to be CK7+/CK20+/p53−/MLH-1+/BRAF wt/K-ras-mutated/MSS cases.
format Online
Article
Text
id pubmed-3587644
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35876442013-03-06 Serrated Pathway Adenocarcinomas: Molecular and Immunohistochemical Insights into Their Recognition Gurzu, Simona Szentirmay, Zoltan Toth, Erika Bara, Tivadar Bara, Tivadar Jung, Ioan PLoS One Research Article INTRODUCTION: Colorectal adenocarcinomas (CRC) developed through serrated pathway seem to present particular behavior compared with the non-serrated ones, but recognition of them is difficult to do. The aim of our paper was to establish some criteria to facilitate their identification. MATERIALS AND METHODS: In 170 consecutive CRCs, we performed immunohistochemical staining with Cytokeratin 7 (CK7) and Cytokeratin 20 (CK20) and also with p53 and MLH-1. At the same time, we analyzed BRAF and K-ras mutations and the microsatellite status of CRC. RESULTS: 26.47% of cases expressed CK7, and 16.47% were CK20-negative. Diffuse positivity for CK7 was associated in the proximal colon with CK20 negativity or weak positivity, BRAF mutations, lack of K-ras mutations, and p53 and MLH-1 negativity. All these cases were microsatellite-unstable and were diagnosed in stage II. Those cases from the distal colon and rectum that expressed CK7 were K-ras-mutated and had low p53 index and MLH-1 positivity, independent of the CK20 expression. CONCLUSIONS: CK7, associated with MLH-1 and p53 expression, and also with the microsatellite status, BRAF and K-ras pattern, might be used to identify the CRC potentially going through serrated pathway. The serrated pathway adenocarcinomas of the proximal colon that do not display the morphological features of this pattern are more frequent CK7+/p53−/MLH-1−/BRAF-mutated/K-ras-wt/MSI cases, but those located in the distal colorectal segments seem to be CK7+/CK20+/p53−/MLH-1+/BRAF wt/K-ras-mutated/MSS cases. Public Library of Science 2013-03-04 /pmc/articles/PMC3587644/ /pubmed/23469219 http://dx.doi.org/10.1371/journal.pone.0057699 Text en © 2013 Gurzu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Gurzu, Simona
Szentirmay, Zoltan
Toth, Erika
Bara, Tivadar
Bara, Tivadar
Jung, Ioan
Serrated Pathway Adenocarcinomas: Molecular and Immunohistochemical Insights into Their Recognition
title Serrated Pathway Adenocarcinomas: Molecular and Immunohistochemical Insights into Their Recognition
title_full Serrated Pathway Adenocarcinomas: Molecular and Immunohistochemical Insights into Their Recognition
title_fullStr Serrated Pathway Adenocarcinomas: Molecular and Immunohistochemical Insights into Their Recognition
title_full_unstemmed Serrated Pathway Adenocarcinomas: Molecular and Immunohistochemical Insights into Their Recognition
title_short Serrated Pathway Adenocarcinomas: Molecular and Immunohistochemical Insights into Their Recognition
title_sort serrated pathway adenocarcinomas: molecular and immunohistochemical insights into their recognition
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587644/
https://www.ncbi.nlm.nih.gov/pubmed/23469219
http://dx.doi.org/10.1371/journal.pone.0057699
work_keys_str_mv AT gurzusimona serratedpathwayadenocarcinomasmolecularandimmunohistochemicalinsightsintotheirrecognition
AT szentirmayzoltan serratedpathwayadenocarcinomasmolecularandimmunohistochemicalinsightsintotheirrecognition
AT totherika serratedpathwayadenocarcinomasmolecularandimmunohistochemicalinsightsintotheirrecognition
AT barativadar serratedpathwayadenocarcinomasmolecularandimmunohistochemicalinsightsintotheirrecognition
AT barativadar serratedpathwayadenocarcinomasmolecularandimmunohistochemicalinsightsintotheirrecognition
AT jungioan serratedpathwayadenocarcinomasmolecularandimmunohistochemicalinsightsintotheirrecognition